Company Valuation: GlaxoSmithKline Pharmaceuticals Limited

Data adjusted to current consolidation scope
Fiscal Period: March 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 281,714 224,319 329,173 487,432 386,822 408,252 -
Change - -20.37% 46.74% 48.08% -20.64% 5.54% -
Enterprise Value (EV) 256,351 207,663 329,173 487,432 386,822 408,252 408,252
Change - -18.99% 58.51% 48.08% -20.64% 5.54% 0%
P/E 16.6x 36.7x 55.8x 52.5x 37.3x 35.5x 31.2x
PBR 10.6x 12.9x 18.5x 25x 17.1x 15.3x 13x
PEG - -0.6x -16.49x 0.9x 3.2x 3.2x 2.3x
Capitalization / Revenue 8.59x 6.9x 9.53x 13x 10.1x 9.73x 8.79x
EV / Revenue 0x 0x 0x 0x 0x 9.73x 8.79x
EV / EBITDA 0x 0x 0x 0x 0x 27.8x 24.5x
EV / EBIT 0x 0x 0x 0x 0x 29.7x 26x
EV / FCF 0x 0x 0x 0x 0x 35.2x 31.8x
FCF Yield 2.75% 1.96% 1.67% 2.6% 2.19% 2.84% 3.15%
Dividend per Share 2 30 32 32 42 57 29.5 29.5
Rate of return 1.8% 2.42% 1.65% 1.46% 2.5% 1.22% 1.22%
EPS 2 100 36.05 34.83 54.76 61.15 67.98 77.28
Distribution rate 30% 88.8% 91.9% 76.7% 93.2% 43.4% 38.2%
Net sales 1 32,780 32,517 34,537 37,492 38,217 41,939 46,453
EBITDA 1 8,273 8,043 9,087 11,774 13,092 14,683 16,675
EBIT 1 7,592 7,385 8,390 11,106 12,428 13,760 15,728
Net income 1 16,947 6,107 5,900 9,276 10,360 11,515 12,873
Net Debt -25,363 -16,656 - - - - -
Reference price 2 1,662.95 1,324.15 1,943.10 2,877.30 2,283.40 2,409.90 2,409.90
Nbr of stocks (in thousands) 169,406 169,406 169,406 169,406 169,406 169,406 -
Announcement Date 5/16/22 5/17/23 5/17/24 5/13/25 5/13/26 - -
1INR in Million2INR
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
35.35x - - 1.23% 4.29B
36.12x13.12x26.72x0.55% 1,102B
28.52x6.55x17.81x2% 643B
31.52x7.52x15.4x2.69% 450B
18.05x4.49x11.1x2.95% 336B
24.01x5.02x14.01x1.74% 298B
21.91x5.62x13.6x2.8% 288B
14.45x5.37x11.03x3.47% 222B
24.08x6.37x11.22x2.74% 199B
-48.34x5.87x32.62x2.38% 169B
Average 18.57x 6.66x 17.06x 2.25% 371.03B
Weighted average by Cap. 24.74x 8.13x 18.84x 1.92%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Valuation GlaxoSmithKline Pharmaceuticals Limited